We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toSession-2-Track-2A-Are-You-Calling-Me-Transparent-Insights-into-Clinical-Trial-Transparency-Layperson-Summaries-and-the-Plain-Language-Initiative

Medical Affairs and Scientific Communications Forum

Medical Communication, MSL, and Medical Writing.

Session 2 Track 2A: Are You Calling Me Transparent? Insights into Clinical Trial Transparency: Layperson Summaries and the Plain Language Initiative

    Session Chair(s)
      David  Meats

      David Meats

      • Global Scientific and Regulatory Documentation
      • Syneos Health, United States
    This session discusses the continuously expanding approach to transparency in pharmaceutical development. We will explore the most current breaking developments in the Clinical Trial Transparency space. In addition, we will cover tips for the development of trial summaries using plain language and what patients and healthcare providers want from these summaries.
      Deborah E. Collyar


      Deborah E. Collyar

      • President
      • Patient Advocates In Research (PAIR), United States
      Theresa  Shalaby, MSN, RN


      Theresa Shalaby, MSN, RN

      • Senior Regulatory Writer
      • Synchrogenix; A Certara Company, United States